Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis

Published:2016-08 Issue:8 Volume:3 Page:e351-e360
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Achhra Amit C,Mwasakifwa Gwamaka,Amin Janaki,Boyd Mark A

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference43 articles.

1. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature;Achhra;AIDS Res Ther,2013

2. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients;Mocroft;AIDS,2010

3. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents;Bedimo;AIDS,2012

4. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study;Worm;J Infect Dis,2010

5. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study;Young;J Acquir Immune Defic Syndr,2015

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiretroviral Therapy Switch in HIV-Infected Adults from a Regional HIV/AIDS Center in NE Romania;Medicina;2024-05-24

2. A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication;International Journal of Molecular Sciences;2024-03-25

3. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV;Viruses;2023-04-10

4. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007–2018;International Journal of Antimicrobial Agents;2023-01

5. Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature;Expert Review of Anti-infective Therapy;2022-11-27